Novo Nordisk is set to cut approximately 9,000 jobs, or about 11% of its global workforce, in a sweeping restructuring move as the company contends with intensifying competition and shifting dynamics in the obesity and diabetes drug markets. The cuts, impacting nearly 5,000 positions in Denmark, come as Novo Nordisk aims to streamline operations, redirect resources, and maintain its edge in the fast-evolving weight loss drug sector dominated by its blockbuster therapies Wegovy and Ozempic.
The announcement follows a period of rapid growth fueled by soaring demand for Wegovy, the first highly effective obesity drug approved in the U.S., which propelled Novo Nordisk to record heights on European stock markets. However, as Eli Lilly and compounded off-brand alternatives eroded Novo’s lead, competition has stiffened, profit projections have been lowered, and company shares have plummeted—shedding nearly half their value this year alone.
New CEO Mike Doustdar, who assumed leadership in August, emphasized the need for a more agile, performance-driven organization: “Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well.” Cost savings of around $1.25 billion annually are projected by late 2026, though the immediate restructuring will result in a one-off charge of about 9 billion Danish crowns (~$1.26 billion).
The layoffs will bring the company’s global headcount back to early 2024 levels and mark the first major action under Doustdar’s leadership. The company says it intends to redirect investment toward its core therapy areas and accelerate research and development as it seeks renewed momentum in an increasingly crowded and consumer-driven market.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!